BRPI0806262A2 - complexo insulinotrópico usando um fragmento de imunoglobulina - Google Patents

complexo insulinotrópico usando um fragmento de imunoglobulina Download PDF

Info

Publication number
BRPI0806262A2
BRPI0806262A2 BRPI0806262-5A BRPI0806262A BRPI0806262A2 BR PI0806262 A2 BRPI0806262 A2 BR PI0806262A2 BR PI0806262 A BRPI0806262 A BR PI0806262A BR PI0806262 A2 BRPI0806262 A2 BR PI0806262A2
Authority
BR
Brazil
Prior art keywords
insulinotropic
insulinotropic peptide
immunoglobulin fragment
complex
peptide conjugate
Prior art date
Application number
BRPI0806262-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Dae Hae Song
Chang Ki Lim
Tae Hun Song
Young Hoon Kim
Se Chang Kwon
Gwan Sun Lee
Sung Youb Jung
In Young Choi
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of BRPI0806262A2 publication Critical patent/BRPI0806262A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
BRPI0806262-5A 2007-01-05 2008-01-04 complexo insulinotrópico usando um fragmento de imunoglobulina BRPI0806262A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20070001662 2007-01-05
PCT/KR2008/000061 WO2008082274A1 (en) 2007-01-05 2008-01-04 An insulinotropic complex using an immunoglobulin fragment

Publications (1)

Publication Number Publication Date
BRPI0806262A2 true BRPI0806262A2 (pt) 2011-08-30

Family

ID=39588830

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0806262-5A BRPI0806262A2 (pt) 2007-01-05 2008-01-04 complexo insulinotrópico usando um fragmento de imunoglobulina

Country Status (20)

Country Link
US (1) US8476230B2 (cg-RX-API-DMAC7.html)
EP (1) EP2114438B8 (cg-RX-API-DMAC7.html)
JP (2) JP2008169195A (cg-RX-API-DMAC7.html)
KR (3) KR101058290B1 (cg-RX-API-DMAC7.html)
CN (3) CN103435699B (cg-RX-API-DMAC7.html)
AR (2) AR065639A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008203574B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0806262A2 (cg-RX-API-DMAC7.html)
CA (1) CA2674538C (cg-RX-API-DMAC7.html)
DK (1) DK2114438T3 (cg-RX-API-DMAC7.html)
ES (1) ES2394121T3 (cg-RX-API-DMAC7.html)
IL (1) IL199566A (cg-RX-API-DMAC7.html)
MX (1) MX2009007267A (cg-RX-API-DMAC7.html)
MY (1) MY164479A (cg-RX-API-DMAC7.html)
NZ (1) NZ577812A (cg-RX-API-DMAC7.html)
PT (1) PT2114438E (cg-RX-API-DMAC7.html)
RU (1) RU2436589C2 (cg-RX-API-DMAC7.html)
TW (1) TWI413528B (cg-RX-API-DMAC7.html)
WO (1) WO2008082274A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200904337B (cg-RX-API-DMAC7.html)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110665B2 (en) * 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
KR101135244B1 (ko) * 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
JP2009019027A (ja) * 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
US9636420B2 (en) 2008-07-23 2017-05-02 Hanmi Science Co., Ltd. Polypeptide complex comprising non-peptidyl polymer having three functional ends
EP2416797A4 (en) 2009-04-10 2013-04-24 Amylin Pharmaceuticals Llc AMYLINAGONIST COMPOUNDS FOR OXYGEN ANIMAL MICE
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
WO2011107990A1 (en) * 2010-03-02 2011-09-09 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
KR20120116942A (ko) 2009-11-23 2012-10-23 아밀린 파마슈티칼스, 인크. 폴리펩티드 접합체
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US9981017B2 (en) 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
KR101324828B1 (ko) * 2010-06-08 2013-11-01 한미사이언스 주식회사 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
KR101382593B1 (ko) * 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
CA2812951A1 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Llc Engineered polypeptides having enhanced duration of action
ES2630031T3 (es) 2010-09-28 2017-08-17 Aegerion Pharmaceuticals, Inc. Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada
WO2012162547A2 (en) 2011-05-25 2012-11-29 Amylin Pharmaceuticals, Inc. Long duration dual hormone conjugates
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
PE20140765A1 (es) 2011-06-10 2014-06-14 Hanmi Science Co Ltd Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos
UA125895C2 (uk) 2011-06-17 2022-07-06 Ханмі Сайенс Ко., Лтд. КОН'ЮГАТ, ЩО МІСТИТЬ ПОХІДНУ ОКСИНТОМОДУЛІНУ ТА Fc-ДІЛЯНКУ ІМУНОГЛОБУЛІНУ, ТА ЙОГО ЗАСТОСУВАННЯ
EP2729481B1 (en) 2011-07-08 2018-10-17 Amylin Pharmaceuticals, LLC Engineered polypeptides having enhanced duration of action with reduced immunogenicity
EP2729160B1 (en) 2011-07-08 2019-03-27 Aegerion Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action and reduced immunogenicity
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
CN103172745A (zh) * 2011-12-21 2013-06-26 北京韩美药品有限公司 包含免疫球蛋白Fc片段的长效人内皮抑素
KR102041412B1 (ko) 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
KR101895047B1 (ko) * 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
KR101665009B1 (ko) * 2012-03-09 2016-10-11 한미사이언스 주식회사 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
AR092862A1 (es) * 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
AR094821A1 (es) * 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
US10441665B2 (en) 2012-07-25 2019-10-15 Hanmi Pharm. Co., Ltd. Liquid formulation of long acting insulinotropic peptide conjugate
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
WO2014064215A1 (en) 2012-10-24 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL
WO2014073842A1 (en) 2012-11-06 2014-05-15 Hanmi Pharm. Co., Ltd. Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
KR20140088837A (ko) 2013-01-03 2014-07-11 한미약품 주식회사 Ｎ-말단 전하가 변형된 인슐린 분비 펩티드 유도체
WO2014133324A1 (ko) * 2013-02-26 2014-09-04 한미약품 주식회사 신규한 인슐린 아날로그 및 이의 용도
KR101895634B1 (ko) * 2013-05-31 2018-09-05 한미약품 주식회사 변이된 힌지 영역을 포함하는 IgG4 Fc 단편
AR096891A1 (es) * 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
AR096890A1 (es) * 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn
MA46146A1 (fr) 2014-01-20 2020-12-31 Hanmi Pharm Ind Co Ltd Insuline a action prolongée et utilisation associée
CN106488933A (zh) * 2014-03-31 2017-03-08 韩美药品株式会社 通过使用免疫球蛋白Fc片段连接改善蛋白质和肽的溶解度的方法
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
KR20150140177A (ko) * 2014-06-05 2015-12-15 한미약품 주식회사 단백질 및 펩타이드의 면역원성을 감소시키는 방법
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
US20160151511A1 (en) * 2014-12-02 2016-06-02 Antriabio, Inc. Proteins and protein conjugates with increased hydrophobicity
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
PE20171154A1 (es) 2014-12-30 2017-08-16 Hanmi Pharm Ind Co Ltd Derivados de glucagon con estabilidad mejorada
ES2805743T3 (es) 2015-03-24 2021-02-15 Inst Nat Sante Rech Med Método y composición farmacéutica para uso en el tratamiento de la diabetes
KR102005456B1 (ko) 2015-06-30 2019-07-30 한미약품 주식회사 신규 글루카곤 유도체 및 이의 지속형 결합체를 포함하는 조성물
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
US11389508B2 (en) * 2015-09-24 2022-07-19 Hanmi Pharm. Co., Ltd. Protein complex by use of a specific site of an immunoglobulin fragment for linkage
MX2018008128A (es) 2015-12-31 2018-12-06 Hanmi Pharm Ind Co Ltd Conjugado persistente de triple activador que activa el receptor de glucagon, glp-1 y gip.
MX2019000019A (es) 2016-06-29 2019-05-06 Hanmi Pharm Ind Co Ltd Derivado de glucagon, conjugado del mismo, composicion que comprende el mismo y uso terapeutico del mismo.
KR102698929B1 (ko) 2016-09-23 2024-08-27 한미약품 주식회사 인슐린 수용체와의 결합력이 감소된, 인슐린 아날로그 및 이의 용도
JOP20190095A1 (ar) * 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
WO2018105988A1 (ko) 2016-12-05 2018-06-14 한미약품 주식회사 면역반응이 약화된 결합체
AU2018215840A1 (en) * 2017-02-03 2019-08-01 Hanmi Pharm. Co., Ltd. Long-Acting Conjugate Of A Physiologically Active Material And Use Thereof
KR101941975B1 (ko) 2017-03-17 2019-01-25 고려대학교 산학협력단 Atpif1을 함유하는 당뇨 치료용 약학조성물
JP7604098B2 (ja) 2017-03-23 2024-12-23 ハンミ ファーマシューティカル カンパニー リミテッド インスリン受容体との結合力が減少されたインスリンアナログの結合体及びその用途
US12297272B2 (en) 2017-08-15 2025-05-13 Eianco US inc. IgG Fc variants for veterinary use
JP7751381B2 (ja) * 2017-09-28 2025-10-08 ハンミ ファーマシューティカル カンパニー リミテッド Ｇｌｐ－２誘導体の持続型結合体
WO2019066603A1 (ko) 2017-09-29 2019-04-04 한미약품 주식회사 효력이 향상된 지속성 단백질 결합체
WO2022266467A2 (en) 2021-06-17 2022-12-22 Dana-Farber Cancer Institute, Inc. Recombinant histone polypeptide and uses thereof
KR20230000682A (ko) 2021-06-25 2023-01-03 한미약품 주식회사 심혈관 질환 또는 신장 기능장애 발생의 위험을 감소시키기 위한 에페글레나타이드

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5401716A (en) * 1987-04-15 1995-03-28 Semiconductor Energy Laboratory Co., Ltd. Method for manufacturing superconducting patterns
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5424686A (en) 1994-04-20 1995-06-13 Philips Electronics North America Corporation Negative-resistance-compensated microwave buffer
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US7157555B1 (en) * 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6815203B1 (en) * 1999-06-23 2004-11-09 Joslin Diabetes Center, Inc. Methods of making pancreatic islet cells
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
DK1355942T3 (da) 2000-12-07 2008-11-17 Lilly Co Eli GLP-1-fusionsproteiner
HUP0303171A2 (hu) 2001-02-19 2003-12-29 Merck Patent Gmbh Csökkentett immunogenitású mesterséges fehérjék
US7790681B2 (en) * 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
US7557183B2 (en) 2003-03-19 2009-07-07 Eli Lilly And Company Polyethylene glycol linked GLP-1 compounds
MXPA05013565A (es) * 2003-06-12 2006-03-09 Lilly Co Eli Proteinas de fusion analogas al glp-1.
DE10352479A1 (de) * 2003-11-07 2005-06-09 Basf Ag Verfahren zur Herstellung von Polymerisatpulvern aus wässrigen Polymerisatdispersionen
EP1682584B1 (en) * 2003-11-13 2013-04-17 Hanmi Science Co., Ltd. A pharmaceutical composition comprising an immunoglobulin fc region as a carrier
JP2006514649A (ja) * 2003-12-17 2006-05-11 アミリン・ファーマシューティカルズ，インコーポレイテッド 腎症の治療および予防のための組成物
AU2004298425A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel GLP-1 analogues linked to albumin-like agents
US7638299B2 (en) * 2004-07-21 2009-12-29 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
CN101044162B (zh) 2004-12-22 2010-10-27 伊莱利利公司 Glp-1类似物融合蛋白质制剂
WO2006076471A2 (en) 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
KR100754667B1 (ko) * 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
CN101166545B (zh) * 2005-05-13 2011-06-15 伊莱利利公司 Glp-1聚乙二醇化的化合物

Also Published As

Publication number Publication date
PT2114438E (pt) 2012-10-11
CN103435700A (zh) 2013-12-11
TW200930408A (en) 2009-07-16
CA2674538A1 (en) 2008-07-10
HK1136504A1 (en) 2010-07-02
JP2008169195A (ja) 2008-07-24
EP2114438B8 (en) 2012-10-03
CN101646451B (zh) 2014-03-26
RU2009129953A (ru) 2011-02-10
KR101058290B1 (ko) 2011-08-22
KR101058315B1 (ko) 2011-08-22
KR20080064750A (ko) 2008-07-09
AU2008203574B2 (en) 2011-12-01
WO2008082274A1 (en) 2008-07-10
EP2114438A4 (en) 2010-09-01
MX2009007267A (es) 2009-11-11
CN103435700B (zh) 2015-12-23
AU2008203574A1 (en) 2008-07-10
KR20110092253A (ko) 2011-08-17
IL199566A (en) 2016-09-29
RU2436589C2 (ru) 2011-12-20
ZA200904337B (en) 2010-10-27
US8476230B2 (en) 2013-07-02
NZ577812A (en) 2012-01-12
DK2114438T3 (da) 2012-12-17
JP5399265B2 (ja) 2014-01-29
CA2674538C (en) 2013-12-17
US20100105877A1 (en) 2010-04-29
AR110853A2 (es) 2019-05-08
CN103435699B (zh) 2015-04-15
AR065639A1 (es) 2009-06-17
KR20100061786A (ko) 2010-06-09
EP2114438A1 (en) 2009-11-11
ES2394121T3 (es) 2013-01-21
CN101646451A (zh) 2010-02-10
JP2010515677A (ja) 2010-05-13
CN103435699A (zh) 2013-12-11
TWI413528B (zh) 2013-11-01
MY164479A (en) 2017-12-29
EP2114438B1 (en) 2012-08-29

Similar Documents

Publication Publication Date Title
BRPI0806262A2 (pt) complexo insulinotrópico usando um fragmento de imunoglobulina
EA200971130A1 (ru) Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
CY1117312T1 (el) Θεραπευτικη αγωγη συνουκλεϊνοπαθειων
CY1119582T1 (el) Υδατικα παρασκευασματα ινσουλινης, που περιεχουν μεθειονινη
CY1118891T1 (el) Συζευγμα ινσουλινης με χρηση θραυσματος ανοσοσφαιρινης
EA201201446A1 (ru) Пептидные производные, их получение и применение
CL2011000663A1 (es) Compuestos derivados de n-heterociclil-2-sulfonil acetamida, moduladores del receptor cb2, utiles para el tratamiento del dolor, enfermedad pulmonar, reumatica, autoinmune, entre otras.
EA201100947A1 (ru) Растворимые полипептиды, предназначенные для применения при лечении аутоиммунных и воспалительных нарушений
MY151245A (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
CY1118984T1 (el) Παρασκευη ενεργων, ακρως φωσφορυλιωμενων, ανθρωπινων λυσοσωμικων ενζυμων σουλφατασης και χρησεις αυτων
DOP2010000379A (es) Compuestos de insulina lispro pegilada
CY1123398T1 (el) Συνθεση συνδυασμου
EA200970287A1 (ru) Способы, соединения, композиции и носители, подходящие для доставки 3-амино-1-пропансульфоновой кислоты
WO2009114776A3 (en) Integrin targeting agents and in-vivo and in-vitro imaging methods using the same
HRP20070432B1 (hr) Gastrorezistentne farmaceutske formulacije koje sadrže rifamicin
EA200801930A1 (ru) Биспецифическая молекула, связывающая tlr9 и cd32 и содержащая t-клеточный эпитоп, для лечения аллергий
WO2009117041A3 (en) Use of pyrene to carry peptides across the blood brain barrier
CY1117603T1 (el) Η λιξισενατιδη ως προσθετο στη μετφορμινη στην θεραπευτικη αγωγη του διαβητη τυπου 2
BRPI0814339A2 (pt) composição farmacêutica, kit para a preparação da composição farmacêutica, conjugado, e, métodos de formação de imagem óptica in vivo do corpo de mamíferos, e de detecção, estabilização, diagnóstico, monitoramento do progresso da doença ou monitoramento do tratamento de um estado doentio do corpon dos mamíferos
BR112014016338A2 (pt) polímeros de polioxazolina e processos para a sua preparação, conjugados destes polímeros e usos médicos dos mesmos
EA201270419A1 (ru) Пролекарства гуанфацина
CY1116544T1 (el) Χρηση της λυσοσωμικης οξινης λιπασης για την αγωγη της ανεπαρκειας λυσοσωμικης οξινης λιπασης σε ασθενεις
WO2007019478A3 (en) Drug delivery from implants using self-assembled monolayers - therapeutic sams
CY1122198T1 (el) Ιατρικο προϊον και θεραπεια
IT1398773B1 (it) Sequenze oligonucleotidiche inibitrici dell'espressione della chimera ciclina d1/trop2 e loro uso in campo medico.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: HANMI HOLDINGS CO., LTD. (KR)

Free format text: TRANSFERIDO DE: HANMI PHARMACEUTICAL CO., LTD.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: HANMI HOLDINGS CO., LTD. (KR)

Free format text: A FIM DE ATENDER AS ALTERACOES DE NOME E ENDERECO REQUERIDAS ATRAVES DA PETICAO NO 20120115905/RJ, DE 13/12/2012, E NECESSARIO APRESENTAR MAIS UMA GUIA RELATIVA AO SEGUNDO SERVICO SOLICITADO, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA.

B25D Requested change of name of applicant approved

Owner name: HANMI SCIENCE CO., LTD. (KR)

B25G Requested change of headquarter approved

Owner name: HANMI SCIENCE CO., LTD. (KR)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]